Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Internal and Emergency Medicine
Published in: Internal and Emergency Medicine 4/2019

01-06-2019 | IM - COMMENTARY

Leptin: a marker of renal injury

Author: Sebastio Perrini

Published in: Internal and Emergency Medicine | Issue 4/2019

Login to get access

Excerpt

Leptin, one of the major adipokines, is a pleiotropic hormone whose plasma levels rise with the increase in adipose tissue. Leptin has a dual role as a hormone and a cytokine. As a hormone, it plays a critical role in regulating appetite, growth, energy and bone metabolism. As a cytokine, leptin participates in the enhancement of some pro-inflammatory responses. Increasing leptin concentrations in serum in obese patients significantly contributes to the low-grade inflammatory state that makes those subjects more prone to develop insulin resistance, type 2 diabetes, cardiovascular and autoimmune diseases [1]. …
Literature
1.
2.
3.
4.
Cha JJ, Hyun YY, Jee YH, Lee MJ, Han KH, Kang YS, Han SY, Cha DR (2013) Plasma concentration of soluble intercellular adhesion molecule-1 (sICAM-1) is elevated in type 2 diabetic patients, and sICAM-1 synthesis is associated with leptin-induced activation of the mitogen-activated protein kinase (MAPK) pathway. Inflammation 201(36):878–887CrossRef
5.
Edeling M, Ragi G, Huang S, Pavenstädt H, Susztak K (2016) Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog. Nat Rev Nephrol 12:426–439CrossRefPubMedPubMedCentral
6.
Harbuzariu A, Rampoldi A, Daley-Brown DS, Candelaria P, Harmon TL, Lipsey CC, Beech DJ, Quarshie A, Ilies GO, Gonzalez-Perez RR (2017) Leptin–Notch signaling axis is involved in pancreatic cancer progression. Oncotarget 8:7740–7752CrossRefPubMed
7.
Wolf G, Hamann A, Han DC, Helmchen U, Thaiss F, Ziyadeh FN, Stahl RA (1999) Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int 56(3):860–872CrossRefPubMed
Metadata
Title
Leptin: a marker of renal injury
Author
Sebastio Perrini
Publication date
01-06-2019
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 4/2019
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-019-02074-8

Other articles of this Issue 4/2019

Internal and Emergency Medicine 4/2019 Go to the issue

CE - MEDICAL ILLUSTRATION

Retroperitoneal dedifferentiated liposarcoma

CE - LETTER TO THE EDITOR

Prevalence and outcome of diuretic resistance in heart failure: reply

IM - ORIGINAL

Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis

CE - LETTER TO THE EDITOR

Intranasal sufentanil given in the emergency department triage zone for severe acute traumatic pain: a randomized double-blind controlled trail—reply

IM - COMMENTARY

Elder abuse: are we turning a blind eye to a crucial issue?

CE - Research Letter to the Editor

Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits